April's 10 most-bought trusts
6th May 2016 13:44
by Kyle Caldwell from interactive investor
Share on
continues to be the most popular investment trust with investors on the Interactive Investor platform.
It was the most-bought trust in April, a feat that has been achieved every single month bar one since February 2014. The exception to the rule was in April 2015, when the trust, one of our sister magazine Money Observer's Rated Funds, was briefly toppled by during its record-breaking £800 million launch.
Woodford Patient Capital has regularly taken the silver medal each month, but has to settle for bronze this time around after being pipped by into second place. The multi-manager trust, another Rated Fund, outsources its portfolio to external fund managers who invest in different regions.
Gold returns to favour
Outside the top three, retained fourth spot. The trust's share price performance has shone of late with a rise of 38% over the past three months, benefiting from gold returning to favour with investors.
But this trust, another Money Observer Rated Fund, is not for the faint-hearted, with the share price still down 45% since May 2015.
Completing the top five is , the biggest riser in the top 10, gaining three places.
The rest of the top 10 are all Money Observer Rated Funds: , , , and , a new entrant into the top 10. The multi-asset trust is described as a wealth preservation fund because it invests in a cautious manner.
The trust that exited the top 10 best-sellers was , managed by Mark Barnett.
| April's 10 most-bought trusts | |||||
|---|---|---|---|---|---|
| Rank | Trust | AIC sector | Change since March | Share price total return 1m to 5 May (%) | Share price total return 3yr to 5 May (%) |
| 1 | Scottish Mortgage* | -- | Global | -2.8 | 59.9 |
| 2 | Witan* | 2 | Global | -1.1 | 29.3 |
| 3 | Woodford Patient Capital | -1 | UK all companies | 4.1 | -- |
| 4 | BlackRock World Mining* | -- | Commodities & natural resources | 9.9 | -44.8 |
| 5 | Bankers* | 3 | Global | 0.6 | 15.1 |
| 6 | City of London* | -1 | UK equity income | 0.5 | 16.4 |
| 7 | Finsbury Income & Growth* | -1 | UK equity income | -3.2 | 35.1 |
| 8 | Biotech Growth* | -1 | Biotechnology & healthcare | -5.5 | 46.9 |
| 9 | Jupiter European Opportunities* | -- | Europe | -1 | 36.2 |
| 10 | RIT Capital Partners* | 2 | Flexible investment | -1.2 | 37.3 |
| *denotes a Money Observer Rated Fund | |||||
This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.